Patents by Inventor Felipe Bedoya

Felipe Bedoya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240398913
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Application
    Filed: December 20, 2023
    Publication date: December 5, 2024
    Inventors: David M. Barrett, Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, JR., Nathan Amar Singh, Zoe Zheng
  • Publication number: 20240228959
    Abstract: The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucleic acid sequence encoding a polypeptide that enhances the immune cell function, or a functional derivative thereof in less than 72 hours; engineered cells generated by the methods, compositions comprising said cells and methods of treating a disease or condition using said cells.
    Type: Application
    Filed: October 6, 2023
    Publication date: July 11, 2024
    Applicant: Kite Pharma, Inc.
    Inventors: Felipe Bedoya, David Barrett, Vijay Gopal Reddy Peddareddigari, Namrata Choudhari, Matthew VanPelt
  • Publication number: 20240132841
    Abstract: The present disclosure provides novel and efficient methods and lentiviral vectors for manufacturing a population of immune cells engineered to express a Chimeric Antigen Receptor (CAR), an engineered T cell receptor (TCR), and/or a nucleic acid sequence encoding a polypeptide that enhances the immune cell function, or a functional derivative thereof in less than 72 hours; engineered cells generated by the methods, compositions comprising said cells and methods of treating a disease or condition using said cells.
    Type: Application
    Filed: October 5, 2023
    Publication date: April 25, 2024
    Applicant: Kite Pharma, Inc.
    Inventors: Felipe Bedoya, David Barrett, Vijay Gopal Reddy Peddareddigari, Namrata Choudhari, Matthew VanPelt
  • Publication number: 20240060089
    Abstract: Disclosed herein, in certain embodiments, are vector-free methods of manufacturing engineered immune cells. In some embodiments, also disclosed herein are compositions comprising engineered immune cells obtained from the methods and processes described herein. In additional embodiments, disclosed herein are methods of treating a disease and kits using engineered immune cells obtained from the methods and processes described herein.
    Type: Application
    Filed: August 26, 2021
    Publication date: February 22, 2024
    Applicant: Tmunity Therapeutics Inc.
    Inventors: Felipe Bedoya, Zoe Zheng
  • Patent number: 11896614
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 13, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: David M. Barrett, Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Nathan Amar Singh, Zoe Zheng
  • Publication number: 20230322923
    Abstract: Described herein are methods for producing and utilizing an artificial antigen presenting cell (aAPC). An aAPC is engineered to express a first and second chimeric stimulatory receptor that specifically bind antigen presenting on a T cell of interest. The aAPC as described herein is designed for use in activating and/or expanding a T cell or chimeric antigen receptor (CAR) T cell. Further, this invention relates to methods of treating cancer by administering to a subject in need thereof an aAPC-activated CAR T cell.
    Type: Application
    Filed: February 6, 2023
    Publication date: October 12, 2023
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Marcela V. Maus, Felipe Bedoya
  • Publication number: 20230295296
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Application
    Filed: January 31, 2023
    Publication date: September 21, 2023
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Publication number: 20230190809
    Abstract: The present invention provides gene edited modified immune cells suitable for adoptive T cell therapy comprising a nucleic acid capable of downregulating CD3?, CD3?, CD3?, B2M, CIITA, TAP1, TAP2, TAPBP, NLRC5, HLA-DM, RFX5, RFXANK, RFXAP, and invariant chain; and further comprising an exogenous nucleic acid encoding a chimeric antigen receptor (CAR), an engineered T cell receptor (TCR), a Killer cell immunoglobulin-like receptor (KIR), dominant negative receptor and/or a switch receptor. Also provided are compositions and methods for generating the modified immune cell, and methods of using the modified immune cells for adoptive therapy and treating a disease or condition.
    Type: Application
    Filed: September 8, 2022
    Publication date: June 22, 2023
    Applicant: Tmunity Therapeutics Inc.
    Inventors: Felipe Bedoya, David Barrett, Vijay Peddareddigari
  • Patent number: 11613574
    Abstract: Described herein are methods for producing and utilizing an artificial antigen presenting cell (aAPC). An aAPC is engineered to express a first and second chimeric stimulatory receptor that specifically bind antigen presenting on a T cell of interest. The aAPC as described herein is designed for use in activating and/or expanding a T cell or chimeric antigen receptor (CAR) T cell. Further, this invention relates to methods of treating cancer by administering to a subject in need thereof an aAPC-activated CART cell.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: March 28, 2023
    Assignee: The General Hospital Corporation
    Inventors: Marcela V. Maus, Felipe Bedoya
  • Publication number: 20210246423
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Application
    Filed: September 18, 2020
    Publication date: August 12, 2021
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Publication number: 20210172020
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 10, 2021
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishek Garg, David Jonathan Glass, Joan Mannick, Jan J. Melenhorst, Michael C. Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
  • Patent number: 10829735
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: November 10, 2020
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Patent number: 10774388
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: September 15, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishek Garg, David Jonathan Glass, Joan Mannick, Jan J. Melenhorst, Michael Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
  • Publication number: 20190330343
    Abstract: Described herein are methods for producing and utilizing an artificial antigen presenting cell (aAPC). An aAPC is engineered to express a first and second chimeric stimulatory receptor that specifically bind antigen presenting on a T cell of interest. The aAPC as described herein is designed for use in activating and/or expanding a T cell or chimeric antigen receptor (CAR) T cell. Further, this invention relates to methods of treating cancer by administering to a subject in need thereof an aAPC-activated CART cell.
    Type: Application
    Filed: January 10, 2018
    Publication date: October 31, 2019
    Inventors: Marcela V. MAUS, Felipe BEDOYA
  • Publication number: 20190292257
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 26, 2019
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, JR., Zoe Zheng
  • Patent number: 10273300
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 30, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Publication number: 20180133296
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Application
    Filed: April 15, 2016
    Publication date: May 17, 2018
    Inventors: David Maxwell Barrett, Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Nathan Amar Singh, Zoe Zheng
  • Publication number: 20170306416
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishnek Garg, David Glass, Joan Mannick, Jan J. Melenhorst, Michael Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
  • Publication number: 20170137783
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Application
    Filed: July 21, 2016
    Publication date: May 18, 2017
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael Milone, Daniel J. Powell, JR., Zoe Zheng
  • Publication number: 20160185861
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Application
    Filed: December 28, 2015
    Publication date: June 30, 2016
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, JR., Zoe Zheng